A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...
More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...
The FDA approved Roche’s diagnostic for triaging women whose primary cervical cancer screenings have tested positive for the human papillomavirus (HPV). The company’s CINtec PLUS Cytology test is ...
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in ...
Multiplex PCR Assay for cobas 4800 system uses self-collected male urine and vaginal swab samples. FDA granted 510(k) clearance for Roche’s cobas® CT/NG Test for detecting Chlamydia trachomatis (CT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback